

Table 4. VLPs vaccine in clinical trial

Cancer type	Tumor antigens	Adjuvants	Expression system	Type of vaccine	Clinical trial identifier	Clinical stage
Vulva and anal cancer	L1	Amorphous, aluminium, hydroxyphosphate sulphate	yeast: <i>Saccharomyces cerevisiae</i>	Therapeutic	NCT03051516	Phase IV
HPV infections	L1	Amorphous, aluminium, hydroxyphosphate sulphate	yeast: <i>Saccharomyces cerevisiae</i>	Prophylactic	NCT03903562	Phase III
Cervical cancer	L1	Amorphous, aluminium, hydroxyphosphate sulphate	yeast: <i>Saccharomyces cerevisiae</i>	Therapeutic	NCT03284866	Phase III
HPV infections	L1	Amorphous, aluminium, hydroxyphosphate sulphate	yeast: <i>Saccharomyces cerevisiae</i>	Prophylactic	NCT04235257	Phase IV
Cervical cancer	L1	Amorphous, aluminium, hydroxyphosphate sulphate	yeast: <i>Saccharomyces cerevisiae</i>	Therapeutic	NCT00092534	Phase III
Pancreatic cancer	-	none	Q β bacteriophage	Therapeutic	NCT04387071	Phase I/II
Melanoma	-	none	Q β bacteriophage	Preventive and Therapeutic	NCT04708418	Phase II
Melanoma		Pembrolizumab (anti-PD-1)	Q β bacteriophage	Therapeutic	NCT02680184	Phase I